ORGO — Organogenesis Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapSuper Stock

Annual income statement for Organogenesis Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	R2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	338	468	451	433	482
Cost of Revenue
Gross Profit	251	354	346	327	366
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	309	397	429	421	483
Operating Profit	28.9	71	22.3	12.5	-1.28
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	17.8	63.8	20.3	10.4	-2.81
Provision for Income Taxes
Net Income After Taxes	17.2	94.9	15.5	4.95	0.861
Net Income Before Extraordinary Items
Net Income	17.2	94.9	15.5	4.95	0.861
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	17.2	94.9	15.5	4.95	-0.937
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.141	0.742	0.13	0.051	0.105